Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC

Yan Yan, Guozhong Jiang, Weijie Ma, Tianhong Li, Liping Wang

Research output: Contribution to journalArticlepeer-review

3 Scopus citations
Original languageEnglish (US)
JournalClinical lung cancer
StateAccepted/In press - 2020


  • Acquired resistance
  • EGFR mutation
  • EML4-ALK Variant 5
  • Histologic transformation
  • Metastatic NSCLC

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this